The Type6 Discovery Platform and Engine take aim at coevolved mechanistic bottlenecks across the human kinome that have remained elusive - until now


With the primary focus on clinically validated kinases, the Type6 team is busy at solving industry wide challenges that have been blunting the therapeutic impact of marketed drugs and clinical stage compounds alike.

Redesigned from the ground up, T6TCs* have broken free from historical limitations within the field, allowing for:

  • exclusive access to a first-in-class MoA that denies tumors access to escape routes

  • potent, ultra-selective, and durable target engagement

  • ID of OFF-state Hits (functional allosteric inhibitors) across the human kinome

Unlike classical inhibitors, T6TCs stabilize cryptic allosteric sites and are capable of delivering the free energy necessary for intercepting kinases in their functionally idle, structurally metastable OFF-states. 

* T6TC: Type6 Therapeutics Compound

The Type6 Platform breathes new life into validated kinases
Purpose-built bivalent probes provide access to OFF-states

Purpose-built OFF-state probes, large-scale compute, and tunable biological readouts provide us with exclusive access to the metastable regime of kinases - enabling OFF-state Target-ID, Hit-ID, Hit-to-Lead, and Lead-opt activities

Type6 Therapeutics: Product-forward, platform-enabled . . .
. . . from OFF-state approach to first-in-class capabilities and assets


Exemplified by our CDK2i lead program, the Type6 platform and engine highlight our broader capabilities and ambitions towards leveraging a vast and thus far hidden therapeutic potential among clinically validated kinases.